Brief: Haisco Pharmaceutical Signs Licensing, R&D Collaboration Agreement With Eli Lilly
BRIEF-Haisco Pharmaceutical Signs Licensing, R&D Collaboration Agreement With Eli Lilly June 1 (Reuters) - Haisco Pharmaceutical 002653.SZ:
SAYS UNIT SIGNED LICENSING, RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT WITH ELI LILLY
SAYS IT IS ENTITLED TO UP TO $87 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS, UP TO $3.0 BILLION IN SUBSEQUENT MILESTONE PAYMENTS UNDER AGREEMENT
Further company coverage: 002653.SZ
(Reporting by Beijing Newsroom)
((Xiuhao.Chen@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)